Prot #AC-055-503: US-based, observational, drug registry of Opsumit® (macitentan) new users in clinical practice

Project: Research project

StatusActive
Effective start/end date5/28/155/28/21

Funding

  • PRA Health Sciences (Prot #AC-055-503)
  • Actelion Pharmaceuticals Ltd. (Prot #AC-055-503)